- A new weight loss drug called survodutide has shown promising results in a phase 3 clinical trial.
- The drugwhich stimulates GLP-1 and glucagon receptorsled to a 16.6% drop in body weight.
- Survodutide also reduced waist circumferencean indicator of metabolic health.
- Experts hope the drug will be useful for both obesity and liver disease; howeverit is not yet approved for use.
Boehringer Ingelheima biopharmaceutical company headquartered in IngelheimGermanyhas announced promising results from its Phase 3 SYNCHRONIZE-1 clinical trial testing survodutide.
Survodutide is a novel dual-action drug designed to treat obesity and related metabolic conditions.
The trialconducted across multiple international sites and involving 725 adults living with obesity or overweight but without type 2 diabetesconcluded in April 2026 after 76 weeks of treatment.
Survodutidewhich activates both glucagon-like peptide-1 (GLP-1) and glucagon receptorsdemonstrated significant and sustained weight loss.
Participants lost an average of 16.6% of their body weighta significant improvement compared to just 3.2% in the placebo group.
Treatment with survodutide also showed meaningful metabolic improvementsincluding reductions in waist circumferencea key predictor of cardiometabolic risk.
These findings demonstrate the drug’s potential to improve overall metabolic health and address obesity-related diseases such as liver dysfunction and metabolic dysfunction-associated steatohepatitis (MASH).
Survodutide (BI 456906) is similar to the active ingredient tirzepatide (MounjaroZepbound) in that it combines two mechanisms of action. Howeverit acts on a different combination of hormone receptors.
While GLP-1 receptor agonists can aid weight loss by reducing appetite and increasing fullness and satietysurvodutide goes a step further by activating glucagon receptorswhich are believed to help regulate metabolic functions in the liver.
This is significant because it may allow an additional reduction in liver fatpotentially helping to reduce liver inflammation and fibrosistwo causes of obesity-related complications.
The SYNCHRONIZE-1 trial evaluated survodutide’s safety and efficacy in adults with overweight or obesityexcluding those with type 2 diabetes.
Participants received weekly injections of survodutide at doses of 3.6 milligrams or 6.0 milligramsor a placeboover nearly a year and a half.
The primary goals of the study were to assess the percentage change in body weight and the proportion of participants achieving at least a 5% reduction in body weight from baseline after 76 weeks of treatment.
According to the researchersup to 85.1% of those treated with survodutide achieved at least a 5% reduction in their weightcontrasting with only 38.8% in the placebo group who reached this goal.
On averagepeople lost 16.6% of their weightwhich was equivalent to about 39.2 pounds. The researchers further noted that this was mainly composed of fat rather than lean muscle tissue.
Another positive indicator was a significant decrease in waist circumference among the participants. Waist circumference is associated with visceral abdominal fatwhich is linked to metabolic dysfunction and cardiovascular risk.
The researchers further reported that common GLP-1 gastrointestinal side effectssuch as nausea and vomitingwere mostly mild to moderate and temporary. These events occurred mainly during the early phase of treatment when the dose was being titrated up. No new safety concerns emerged during the trial.
Full data from the study will be presented at the American Diabetes Association (ADA) 2026 Scientific Sessions in June 2026.
Hector PerezMDlead bariatric surgeon at Renew Bariatrics and an advisor at Bariatric Reportstold Healthline that when it comes to weight lossit’s too early to call survodutide a “game-changer.”
“[W]hile the reported weight loss number is impressivewe already have very strong performers in this category,” he said.
Perezwho was not involved in the SYNCHRONIZE-1 trialcautioned that the full data should be made available before any claims are made about its side effects.
“In real lifethe best drug is often the one patients can actually stay on,” he said.
Howeversurvodutide acts on multiple metabolic pathwaysso it could be useful beyond its appetite-suppressing effectsPerez noted.
“I’m personally most interested [in] liver disease because a lot of my patients don’t just have obesitythey have fatty liverelevated liver enzymesinsulin resistanceand visceral fat,” he said.
Survodutide may treat liver disease by addressing the underlying metabolic problems that cause fatty liversuch as excess body fatinsulin resistanceand inflammation.
Its ability to reduce appetite can lower the amount of fat stored in the liverPerez explained.
On the other handits glucagon-based action could help the body burn more fatincluding harmful visceral and liver fat.
This could lead to improved liver enzymesless liver inflammationand slower progression of scarring.
“In simple termsit may help the liver heal by improving the whole metabolic system,” said Perez. “If this drug truly improves liver inflammation and fibrosis markers while driving weight lossthat’s where it could carve out a real niche.”
Kristin Kuminskia registered dietitian nutritionist with The RX Indexwho wasn’t involved in the trialcalled the results “significant,” placing survodutide at a similar level of efficacy to tirzepatide.
Howevershe said that any questions you ask your physician should focus on how it compares to existing weight loss drugs as far as side effectsand how it performs for people with co-existing conditions like fatty liver disease.
“It’s not yet approvedso the conversation with a doctor right now is about what’s in the pipelinewhether current GLP-1 options are workingand whether to watch for survodutide trials to participate in,” she said.
Perez added that you should also discuss other practical questions with your doctor before taking a weight loss medicationsuch as whether you are a good candidate for bariatric surgery.
“[M]any people lose years trying medications when surgery would have given them a better long-term outcome,” he said.
You should also ask whether weight loss is realistic for your bodyhow to protect muscle while losing weightwhat side effects you can expectwhat happens when you stop taking the medicationand whether your insurance covers your treatment.
“Basicallymy advice is to choose your treatment according to your bodyyour habitsyour financesand what you can realistically sustain for years instead of getting impressed with a shiny new drug,” Perez said.